On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

HealthDay News — For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published ...

New weight management drugs could be used to create a global metabolic health revolution and improve longevity, if investment ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

In short, semaglutide can help people with diabetes improve their blood sugar and lose weight. Higher doses seem to work ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.